Description

CJC-1295 With DAC + Ipamorelin + GHRP-2 Blend Peptide Vials

CJC-1295 With DAC + Ipamorelin + GHRP-2 Blend consists of three compounds blend contains 2mg CJC-1295 With DAC, 2mg Ipamorelin, and 2mg GHRP-2, totaling 6mg.

CJC – 1295 DAC Peptide
CAS number	863288-34-0
Molar Mass	3367.954 g·mol−1
Chemical Formula	C152H252N44O42
IUPAC Name	CJC 1295 (DAC-GRF)

Ipamorelin
CAS number	170851-70-4
Molar Mass	711.868 g·mol−1
Chemical Formula	C38H49N9O5
IUPAC Name	(2S)-6-Amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(4H-imidazol-4-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide

GHRP-2
CAS Number	158861-67-7
Molar Mass	817.992 g·mol−1
Chemical Formula	C45H55N9O6
IUPAC Name	(2S)-6-Amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide

Introduction

The CJC-1295 With DAC + Ipamorelin + GHRP-2 Blend is a research formulation designed exclusively for scientific investigations. This blend combines CJC-1295 With DAC, Ipamorelin, and GHRP-2, offering a multifaceted approach to research on growth hormone-related processes.

Key Characteristics

CJC-1295 With DAC is known for its extended half-life, potentially leading to prolonged effects on growth hormone release. Ipamorelin is recognized for its ability to stimulate growth hormone secretion, potentially influencing various physiological functions. GHRP-2 is a peptide that may stimulate the release of growth hormone, contributing to research on muscle growth and other related aspects.

Research Applications

This research blend is formulated for scientific exploration into growth hormone-related processes. Researchers may investigate its applications in diverse research models to gain insights into the synergistic effects of its components.

Research Benefits

Potential Synergistic Benefits

Researchers may explore the combined effects of CJC-1295 With DAC, Ipamorelin, and GHRP-2, assessing potential synergies that could enhance the understanding of growth hormone regulation.

CJC-1295 and IGF-1

Studies may focus on the interplay between CJC-1295 With DAC and insulin-like growth factor 1 (IGF-1), exploring potential implications for growth-related processes.

Ipamorelin and Weight Management Research

Research may investigate the role of Ipamorelin in influencing weight gain, contributing to a comprehensive understanding of its impact on composition.

GHRP-2 May Potentially Improve Muscle Growth

Researchers may explore the potential of GHRP-2 to enhance muscle growth, providing valuable insights into its applications in muscle-related research.

Summary

The CJC-1295 With DAC + Ipamorelin + GHRP-2 Blend is a research formulation offering a comprehensive approach to the study of growth hormone-related processes. Researchers are encouraged to explore its potential synergistic benefits and individual contributions to gain a deeper understanding.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Yamamoto D, Ikeshita N, Matsubara T, Tasaki H, Herningtyas EH, Toda K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 2008 Feb 27;82(9-10):460-6. doi: 10.1016/j.lfs.2007.11.019. Epub 2007 Dec 5. PMID: 18191156. [Read More].
2. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001 Jan 12;280(1):132-8. doi: 10.1006/bbrc.2000.4065. PMID: 11162489. [Read More].
3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. [Read More].